hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06325124, orgStudyIdInfo id: REC/01805 MARIA NAWAZ, briefTitle: Muscle Energy Technique of Lower Limb Muscles in Forward Head Posture, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2025-03-20, completionDateStruct date: 2025-04-20, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Riphah International University, class: OTHER, descriptionModule briefSummary: The aim of this randomized controlled trial is to find the effect of muscle energy technique of muscles involved in lower limb superficial backline (hamstring and Gastro-soleus) on improving craniovertebral angle and cervical proprioception and minimizing pain among patients with forward head posture, conditionsModule conditions: Forward Head Posture, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Muscle energy technique, interventions name: Conventional PT, outcomesModule primaryOutcomes measure: Neck disability index (NDI), primaryOutcomes measure: Numeric Pain Rating Scale NPRS, secondaryOutcomes measure: Bubble inclinometer, secondaryOutcomes measure: FHP Mobile Application (To measure Craniovertebral angle), secondaryOutcomes measure: Cervical Joint Position Error, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: We Care Physical Therapy Clinic street 13 phase 4A, Ghouri town Islamabad, status: RECRUITING, city: Islamabad, state: Punjab, country: Pakistan, contacts name: KINZA ANWAR, MS-OMPT, role: CONTACT, phone: +92-3239735427, email: kinza.anwar@riphah.edu.pk, contacts name: MARIA NAWAZ, MS-OMPT*, role: CONTACT, phone: +92-3435625466, contacts name: MARIA NAWAZ, role: SUB_INVESTIGATOR, geoPoint lat: 33.72148, lon: 73.04329, hasResults: False
protocolSection identificationModule nctId: NCT06325111, orgStudyIdInfo id: RC 06/2023, briefTitle: Determinants of Glycaemic Control in Children With Type 1 Diabetes, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-29, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2026-04-30, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: IRCCS Burlo Garofolo, class: OTHER, descriptionModule briefSummary: Type 1 diabetes (T1D) is a common chronic disease of childhood associated with a significantly increased risk of micro- and macro-vascular complications, including neuropathy, nephropathy and cardiovascular diseases. The risk of development T1D comorbidities is associated with glycaemic control, a complex mechanism involving biological, physiological environmental factors.While more than 60 genetic variants were already associated with Glycated hemoglobin (HbA1c) in healthy subjects, very few genes have been identified in T1D individuals. Also, hyperglycaemia could be the cause of epigenetic changes at specific target genes, such as DNA methylation, histone modifications and microRNAs, correlated to accelerated development of diabetes-related complications. Most recently, increasing evidence also suggested that human microbiome may play a crucial role in the onset and progression of T1D and dysbiosis of the gut and oral microbiota was reported as a typical feature of hyperglycaemia.However, potential differences among poorly and good managed T1D subjects have not been still studied. Also, the exact mechanism by long-term hyperglycaemia's acts in T1D remains poorly understood. Therefore, this project will explore an emerging area of research by the study of possible genetic, epigenetic and environmental biomarkers among T1D subjects with different glycaemic control., conditionsModule conditions: Diabetes Mellitus, Type 1, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 800, type: ESTIMATED, armsInterventionsModule interventions name: Determinants of T1D glycaemic control, outcomesModule primaryOutcomes measure: Identification of genes involved in T1D glycaemic control, primaryOutcomes measure: Identification of DNA methylation patterns involved in T1D glycaemic control, primaryOutcomes measure: Identification of microRNAs involved in T1D glycaemic control, primaryOutcomes measure: Identification of oral microbiome characteristics associated to T1D glycaemic control, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 20 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", status: RECRUITING, city: Trieste, zip: 34137, country: Italy, contacts name: Eulalia Catamo, BSc, role: CONTACT, phone: +39 040.3785470, email: eulalia.catamo@burlo.trieste.it, geoPoint lat: 45.64953, lon: 13.77679, hasResults: False
protocolSection identificationModule nctId: NCT06325098, orgStudyIdInfo id: PER-NEPH, briefTitle: Implementation of a Diagnostic Workflow for Personalized Diagnosis of Nephrotic Syndrome, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-01-26, primaryCompletionDateStruct date: 2026-01-31, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Meyer Children's Hospital IRCCS, class: OTHER, descriptionModule briefSummary: Nephrotic syndrome (NS) is a clinical picture common to several diseases resulting from damage to podocytes and glomerular filtration barrier. Currently, there is limited consensus regarding the diagnostic pathway and management of the specific etiology. Some patients show complete response to first-line steroid therapy (steroid-sensitive nephrotic syndrome, SSNS), especially in children and young adults. The prognosis of this group is generally favorable. In contrast, patients unresponsive to steroids (steroid-resistant NS, SRNS) frequently undergo immunosuppressive therapies, which are burdened with numerous side effects. Resistance to treatment is associated with a high likelihood of progression to chronic renal disease (CKD) and kidney failure (ESKD). Recent evidence suggests that immunological mechanisms (including permeabilizing factors) are involved in the pathogenesis of post-transplant NS recurrence and SSNS.Providing patients with NS with a correct diagnosis is the cornerstone of personalized medicine, reducing morbidity and side effects of therapies, ensuring their appropriate prescription, and slowing or preventing progression to ESKD., conditionsModule conditions: Nephrotic Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Patients with nephrotic syndrome (SSNS, SRNS), primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Anti-nephrin antibodies, interventions name: u-RPC cultures, outcomesModule primaryOutcomes measure: Role of anti-nephrin antibodies in the pathogenesis of NS, secondaryOutcomes measure: Functional role of VUS in the pathogenesis of SRNS, secondaryOutcomes measure: Identification of potential predictive biomarkers of renal outcome., secondaryOutcomes measure: Cost-effectiveness analysis, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 40 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Meyer Children's Hospital IRCCS, status: RECRUITING, city: Firenze, country: Italy, contacts name: Paola Romagnani, role: CONTACT, geoPoint lat: 43.77925, lon: 11.24626, hasResults: False
protocolSection identificationModule nctId: NCT06325085, orgStudyIdInfo id: Ayesha Saddiqa, briefTitle: Compensatory and Restorative Rehabilitation Techniques in Stroke, acronym: The, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-16, primaryCompletionDateStruct date: 2025-03-20, completionDateStruct date: 2025-04-20, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Riphah International University, class: OTHER, descriptionModule briefSummary: The aim of this randomized controlled trial is to find the combined effects of restorative and compensatory cognitive rehabilitation techniques in mild cognitive impairment after stroke., conditionsModule conditions: Cognitive Impairment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: compensatory and restorative rehabilitation techniques, interventions name: Traditional cognitive rehabilitation training, outcomesModule primaryOutcomes measure: Montreal cognitive assessment test (Urdu version), primaryOutcomes measure: Cognitive assessment scale for stroke patients (CASP), secondaryOutcomes measure: Stroke specific quality of life questionnaire (Urdu version), secondaryOutcomes measure: Modified Rankin Scale (MRS), eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shafi Hospital Dina, status: RECRUITING, city: Dina, state: Punjab, country: Pakistan, contacts name: Dr. Aroosa Tariq, MS:NMPT, role: CONTACT, phone: 03161578156, email: aroosa.tariq@riphah.edu.pk, contacts name: Ayesha Saddiqa, MS:NMPT*, role: CONTACT, phone: 0315-5568417, email: aisha.sadeeqa23@gmail.com, contacts name: Dr. Aroosa Tariq, MS:NMPT, role: PRINCIPAL_INVESTIGATOR, contacts name: Ayesha Saddiqa, MS:NMPT*, role: SUB_INVESTIGATOR, hasResults: False
protocolSection identificationModule nctId: NCT06325033, orgStudyIdInfo id: 18546, briefTitle: Prospective Validation of the Eleveld Model of Propofol for Procedural Sedation in Adults., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: University Medical Center Groningen, class: OTHER, descriptionModule briefSummary: The goal of this prospective observational study is to identify effect site concentrations (CET) of propofol using the Eleveld model for different levels of procedural sedation.The main question it aims to answer is to identify CET propofol using the Eleveld model for different levels of procedural sedation as measured by the modified observer's assessment of alertness and sedation score (MOAAS) and EEG monitoring.Participants vital signs will be monitored according to the departmental protocol. Sedation will be administered using Target-Controlled Infusion (TCI) of propofol (administered by effect-site TCI using the Eleveld model) and remifentanil (administered by effect site TCI using the Eleveld model). Target controlled infusion of propofol and remifentanil is according to the departmental protocol. The MOAAS score will be noted every 5 minutes or when the target effect site concentration of propofol is altered. Depth of sedation will also be monitored using a non-invasive BIS® monitor., conditionsModule conditions: Deep Sedation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: To identify effect-site target concentrations of propofol for the Eleveld model that are associated with moderate to deep sedation levels, MOAAS 3-1 and the associated BIS levels in adult patients., secondaryOutcomes measure: Induction time, secondaryOutcomes measure: Recovery time, secondaryOutcomes measure: Adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2023-11-23, uploadDate: 2024-02-29T03:59, filename: Prot_000.pdf, size: 454063, hasResults: False
protocolSection identificationModule nctId: NCT06324994, orgStudyIdInfo id: YY-20394-BV-MCL, briefTitle: Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2026-12-01, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Dalian Medical University, class: OTHER, descriptionModule briefSummary: This is a single arm, open label, national multicenter clinical study included patients with relapsed and refractory blastoid variant of mantle cell lymphoma (R/R BV-MCL), aiming to evaluate the efficacy of a chemotherapy free triple therapy of PI3K inhibitor (Linperlisib) combined with anti-CD20 monoclonal antibody (Obinutuzumab) and BCL-2 inhibitor (Venetoclax) in R/R BV-MCL patients., conditionsModule conditions: Mantle Cell Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Linperlisib in combination with Obinutuzumab and Venetoclax, outcomesModule primaryOutcomes measure: Objective Response Rate (ORR) according to the RECIST 1.1, secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Duration of Overall Response (DOR), secondaryOutcomes measure: Adverse event (AE), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Second Hospital Dalian Medical University, city: Dalian, state: Liaoning, zip: 116000, country: China, contacts name: Xiuhua Sun, Doctor, role: CONTACT, phone: +86 17709873631, email: 3038668@vip.sina.com, geoPoint lat: 38.91222, lon: 121.60222, hasResults: False
protocolSection identificationModule nctId: NCT06324968, orgStudyIdInfo id: 22-AOIP-01, briefTitle: Ro60 Expression in Macrophages in Sjogren's Disease, acronym: RoMioSS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-09, primaryCompletionDateStruct date: 2025-02-09, completionDateStruct date: 2026-02-09, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire de Nice, class: OTHER, descriptionModule briefSummary: Context: The Ro60 protein associates with YRNAs (or RNYs) to form the RoRNP complex, which regulates RNA surveillance and maturation. It is hypothesized that its impairment by nuclear penetration of the anti-Ro60 autoantibodies, would deregulate the anti-inflammatory response in monocytes/macrophages (Mo/Mp) in patients with Sjögren's disease (SD)., conditionsModule conditions: Sjogren's Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Positive serology for anti-SSA, outcomesModule primaryOutcomes measure: SSA/Ro60 interactions, secondaryOutcomes measure: The molecular and functional impact : inflammatory cytokine and chemokine profiles, secondaryOutcomes measure: The molecular and functional impact : cell apoptosis/survival and cellular polarization, secondaryOutcomes measure: The molecular and functional impact : clinical and biochemical phenotypes of CD14+ monocytes/macrophages, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU Nice, status: RECRUITING, city: Nice, state: Alpes-Mritimes, zip: 06000, country: France, contacts name: Nihal MARTIS, MD, MSc, role: CONTACT, phone: 4 92035444, phoneExt: +33, email: martis.n@chu-nice.fr, geoPoint lat: 43.70313, lon: 7.26608, hasResults: False
protocolSection identificationModule nctId: NCT06324955, orgStudyIdInfo id: IRB-P00042507, briefTitle: Language During Inhalational Induction, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-11, primaryCompletionDateStruct date: 2024-07-01, completionDateStruct date: 2025-03-11, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Boston Children's Hospital, class: OTHER, descriptionModule briefSummary: The aim of this study is to compare the impact of common (standard of care) language vs positive language used by clinicians during inhalational induction of anesthesia on anxiety and negative behaviors in children. This is a prospective randomized parallel group trial. Patients will be randomized 1:1 to the common/standard language group or the positive language group., conditionsModule conditions: Emergence Delirium, conditions: Anesthesia; Adverse Effect, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 128, type: ESTIMATED, armsInterventionsModule interventions name: Standard/common language during induction, interventions name: Positive language during induction, outcomesModule primaryOutcomes measure: Induction compliance, secondaryOutcomes measure: Length of induction, secondaryOutcomes measure: Verbal refusal of mask, eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 10 Years, stdAges: CHILD, contactsLocationsModule locations facility: Boston Children's Hospital, city: Boston, state: Massachusetts, zip: 02115, country: United States, contacts name: John Fiadjoe, MD, role: CONTACT, email: john.fiadjoe@childrens.harvard.edu, contacts name: Rachel Bernier, MPH, role: CONTACT, phone: 857-218-5348, email: rachel.bernier@childrens.harvard.edu, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06324942, orgStudyIdInfo id: REB24-0349, briefTitle: Analgesic Efficacy of Surgeon-administered Transversus Abdominis Plane Blocks for Caesarean Section., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: University of Calgary, class: OTHER, descriptionModule briefSummary: The purpose of this research study is to evaluate whether or not adding a Transversus Abdominis Plane Block (TAP block) improves pain control for patients having a cesarean section. A TAP block is a type of nerve block where at the end of the surgery an injection of a long acting local anesthetic is made into the abdominal wall. In studies in patient's having other abdominal surgeries this has reduced the amount of narcotics patients need for pain control. This may also led to patients being more active after surgery and maybe spending less time in hospital., conditionsModule conditions: Cesarean Section Complications, conditions: Pain, Postoperative, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg, outcomesModule primaryOutcomes measure: Post operative Pain, secondaryOutcomes measure: Time to first request for rescue analgesia in hours, secondaryOutcomes measure: Post operative Opioid use, secondaryOutcomes measure: Time from surgery to discharge from hospital, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Calgary, city: Calgary, state: Alberta, zip: T2N 2T9, country: Canada, geoPoint lat: 51.05011, lon: -114.08529, hasResults: False
protocolSection identificationModule nctId: NCT06324916, orgStudyIdInfo id: vascularized fibular graft, briefTitle: Donor Site Morbidity After Free Vascularized Fibular Graft, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-10, primaryCompletionDateStruct date: 2026-01-10, completionDateStruct date: 2026-12-30, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: This study was carried out at Assiut University to Asses the long-term donor site morbidity following free vascularized fibular transfer because there is a limited information regarding the long-term donor morbidity of this type of flap., conditionsModule conditions: Osteosarcoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Xray, outcomesModule primaryOutcomes measure: Donor site morbidity in contrast with surgery benifits this will be measured by point evaluation system, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Assiut university, status: RECRUITING, city: Assiut, country: Egypt, geoPoint lat: 27.18096, lon: 31.18368, hasResults: False
protocolSection identificationModule nctId: NCT06324903, orgStudyIdInfo id: echo cath CHD, briefTitle: Role of Echocardiography in Optimization of Cardiac Catheterization in Children With Congenital Heart Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-10-30, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Delineate and evaluate the role of echocardiography in children with congenital heart disease undergoing cardiac catheterization in the pediatric cardiology unit of Assiut university hospitals.1. To improve diagnostic accuracy by creating a systematic approach for image acquisition and interpretation across different procedural timepoints.2. To promote consistent hemodynamic evaluations to reliably assess cardiac function and blood flow.3. To enable optimized procedural planning and intraprocedural guidance via comprehensive delineation of anatomy and pathophysiology.4. To facilitate standardized longitudinal monitoring after interventions to evaluate outcomes and detect complications., conditionsModule conditions: Echocardiography, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 67, type: ESTIMATED, armsInterventionsModule interventions name: echocardiography and percutaneous cardiac catheterization, outcomesModule primaryOutcomes measure: congenital heart defect dimensions in mm,, primaryOutcomes measure: pressure gradient in mmHg across valve, secondaryOutcomes measure: cardiac function by measuring fraction shortening (FS) % in percent, secondaryOutcomes measure: cardiac function TAPSV in cm/sec, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False